BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9721851)

  • 1. Rare loss-of-function mutation of a death receptor gene in head and neck cancer.
    Pai SI; Wu GS; Ozören N; Wu L; Jen J; Sidransky D; El-Deiry WS
    Cancer Res; 1998 Aug; 58(16):3513-8. PubMed ID: 9721851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
    Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Jang JJ; Han JY; Lee JY; Yoo NJ
    Cancer Res; 1999 Nov; 59(22):5683-6. PubMed ID: 10582684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.
    Adams J; Cuthbert-Heavens D; Bass S; Knowles MA
    Cancer Lett; 2005 Apr; 220(2):137-44. PubMed ID: 15766588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.
    Wu GS; Burns TF; Zhan Y; Alnemri ES; El-Deiry WS
    Cancer Res; 1999 Jun; 59(12):2770-5. PubMed ID: 10383128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
    Takimoto R; El-Deiry WS
    Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas.
    Gunduz M; Nagatsuka H; Demircan K; Gunduz E; Cengiz B; Ouchida M; Tsujigiwa H; Yamachika E; Fukushima K; Beder L; Hirohata S; Ninomiya Y; Nishizaki K; Shimizu K; Nagai N
    Gene; 2005 Aug; 356():109-17. PubMed ID: 15935570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.
    Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Kang CS; Kim KM; Jang JJ; Nam SW; Lee JY; Yoo NJ
    Oncogene; 2001 Jan; 20(3):399-403. PubMed ID: 11313970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
    Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
    Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.
    Shetty S; Graham BA; Brown JG; Hu X; Vegh-Yarema N; Harding G; Paul JT; Gibson SB
    Mol Cell Biol; 2005 Jul; 25(13):5404-16. PubMed ID: 15964798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers.
    Gunduz M; Ouchida M; Fukushima K; Ito S; Jitsumori Y; Nakashima T; Nagai N; Nishizaki K; Shimizu K
    Oncogene; 2002 Jun; 21(28):4462-70. PubMed ID: 12080476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL-R4-beta: a new splice variant of TRAIL-receptor 4 lacking the cysteine rich domain 1.
    Krieg A; Schulte am Esch J; Ramp U; Hosch SB; Knoefel WT; Gabbert HE; Mahotka C
    Biochem Biophys Res Commun; 2006 Oct; 349(1):115-21. PubMed ID: 16934748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene.
    Wu GS; Burns TF; McDonald ER; Jiang W; Meng R; Krantz ID; Kao G; Gan DD; Zhou JY; Muschel R; Hamilton SR; Spinner NB; Markowitz S; Wu G; el-Deiry WS
    Nat Genet; 1997 Oct; 17(2):141-3. PubMed ID: 9326928
    [No Abstract]   [Full Text] [Related]  

  • 14. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss.
    Maestro R; Piccinin S; Doglioni C; Gasparotto D; Vukosavljevic T; Sulfaro S; Barzan L; Boiocchi M
    Cancer Res; 1996 Mar; 56(5):1146-50. PubMed ID: 8640775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA.
    Frost GI; Mohapatra G; Wong TM; Csóka AB; Gray JW; Stern R
    Oncogene; 2000 Feb; 19(7):870-7. PubMed ID: 10702795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
    Wu WG; Soria JC; Wang L; Kemp BL; Mao L
    Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
    Lerman MI; Minna JD
    Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms.
    Fernàndez V; Jares P; Beà S; Salaverria I; Guino E; de Sanjosé S; Colomer D; Ott G; Montserrat E; Campo E
    Haematologica; 2004 Nov; 89(11):1322-31. PubMed ID: 15531454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.